Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Acquires Tissue Microarray IP

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today announced the acquisition of a portfolio of six patents and applications related to tissue microarrays for an undisclosed amount.

Nuclea acquired the IP from Laurus Master Fund, a division of Laurus Capital Management. Clinomics Biosciences previously owned the IP and assigned it to Laurus, but since then, the patents have not been maintained, Nuclea said, adding that it plans to petition the US Patent and Trademark Office immediately to revive them.

Nuclea President and CEO Patric Muraca is the inventor of all the technologies in the patent portfolio purchased from Laurus. He was previously the president and COO of Clinomics.

"We believe these patents will allow Nuclea to expand our product offering and drive significant licensing revenue for the company," Muraca said in a statement. "The tissue microarray technologies contained in this portfolio are very useful in specimen analysis, and we are eager to integrate them into our research."

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.